Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Figure 2

OX40/OX40L expression on the peripheral blood lymphocytes and plasma in different stages of MG patients. (a) Representative expression of OX40 and OX40L on CD4⁺ T cells, CD19⁺ B cells, and CD14⁺ mononuclear cells in MG patients at baseline, in relapse and in remission. The red lines indicate specific staining results measured by flow cytometry, and the blue lines indicate isotype controls. (b) Comparison of OX40 expression on CD4⁺ T cells in MG patients at baseline, in remission, and in relapse. (c) Comparison of OX40L expression on CD19⁺ B cells in MG patients at baseline, in remission, and in relapse. (d) Comparison of OX40L expression on CD14⁺ mononuclear cells in MG patients at baseline, in remission, and in relapse. (e) Comparison of sOX40 plasma levels in MG patients at baseline, in remission, and in relapse. (f) Comparison of sOX40L plasma levels in MG patients at baseline, in remission, and in relapse.

(a)

(b)

(c)

(d)

(e)

(f)